Found 517 results
Author [ Keyword(Desc)] Title Type Year
Filters: Author is Ho, Emily  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Humans
Madeen EP, Löhr CV, You H, Siddens LK, Krueger SK, Dashwood RH, Gonzalez FJ, Baird WM, Ho E, Bramer L et al..  2017.  Dibenzo[def,p]chrysene transplacental carcinogenesis in wild-type, Cyp1b1 knockout, and CYP1B1 humanized mice.. Mol Carcinog. 56(1):163-171.
Parasramka MA, Ho E, Williams DE, Dashwood RH.  2012.  MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals.. Mol Carcinog. 51(3):213-30.
Atwell LL, Zhang Z, Mori M, Farris P, Vetto JT, Naik AM, Oh KY, Thuillier P, Ho E, Shannon J.  2015.  Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.. Cancer Prev Res (Phila). 8(12):1184-1191.
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Wang R, Yu Z, Sunchu B, Shoaf J, Dang I, Zhao S, Caples K, Bradley L, Beaver LM, Ho E et al..  2017.  Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.. Aging Cell. 16(3):564-574.
Nian H, Delage B, Ho E, Dashwood RH.  2009.  Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.. Environ Mol Mutagen. 50(3):213-21.
Rajendran P, Kidane AI, Yu T-W, Dashwood W-M, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.  2013.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.. Epigenetics. 8(6):612-23.
Abbas A, J Hall A, Patterson WL, Ho E, Hsu A, Al-Mulla F, Georgel PT.  2016.  Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.. Biochem Cell Biol. 94(1):71-81.
Song Y, Chung CS, Bruno RS, Traber MG, Brown KH, King JC, Ho E.  2009.  Dietary zinc restriction and repletion affects DNA integrity in healthy men.. Am J Clin Nutr. 90(2):321-8.
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Chen Y-S, Wang R, Dashwood W-M, Löhr CV, Williams DE, Ho E, Mertens-Talcott S, Dashwood RH.  2017.  A miRNA signature for an environmental heterocyclic amine defined by a multi-organ carcinogenicity bioassay in the rat.. Arch Toxicol. 91(10):3415-3425.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Myzak MC, Tong P, Dashwood W-M, Dashwood RH, Ho E.  2007.  Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.. Exp Biol Med (Maywood). 232(2):227-34.
Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E.  2017.  The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.. J Nutr Biochem. 47:113-119.
Beaver LM, Kuintzle R, Buchanan A, Wiley MW, Glasser ST, Wong CP, Johnson GS, Chang JH, Löhr CV, Williams DE et al..  2017.  Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer.. J Nutr Biochem. 42:72-83.
Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM, E Houseman A, Williams DE, Dashwood RH, Ho E.  2014.  Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.. PLoS One. 9(1):e86787.
Ho E, Song Y.  2009.  Zinc and prostatic cancer.. Curr Opin Clin Nutr Metab Care. 12(6):640-5.

Pages